Log In
Print this Print this

Lucanix belagenpumatucel-L

  Manage Alerts
Collapse Summary General Information
Company Activate Immunotherapy
DescriptionAllogeneic vaccine consisting of 4 genetically modified non-small cell lung cancer (NSCLC) cell lines to secrete antisense oligonucleotides against TGFB2
Molecular Target Transforming growth factor (TGF) beta 2 (TGFB2)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat advanced non-small cell lung cancer (NSCLC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today